Epidemiology and etiology of urinary tract infections in the community. Antimicrobial susceptibility of the main pathogens and clinical significance of resistance;Epidemiología y etiología de la infección urinaria comunitaria. Sensibilidad antimicrobiana de los principales patógenos y significado clínico de la resistencia

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 23, Issue SUPPL.4, 2005, Pages 3-8

  Alós, Juan Ignacio ^a  

^a HOSPITAL DE MÓSTOLES   (Spain)

Author keywords

Antibiotics; Antimicrobial resistance; Epidemiology; Urinary infection

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFIXIME; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN; NITROFURANTOIN; PIPEMIDIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; CATHETERIZATION; CYSTITIS; DIABETES MELLITUS; ESCHERICHIA COLI; HUMAN; KLEBSIELLA; PROTEUS MIRABILIS; PYELONEPHRITIS; REVIEW; SPINAL CORD INJURY; STAPHYLOCOCCUS SAPROPHYTICUS; STREPTOCOCCUS AGALACTIAE; URINARY TRACT INFECTION; ADOLESCENT; ADULT; AGED; COMMUNICABLE DISEASE; DRUG EFFECT; DRUG RESISTANCE; ENTEROBACTER INFECTION; ENTEROBACTERIACEAE; FEMALE; MALE; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; ONSET AGE; RISK FACTOR; STAPHYLOCOCCUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS; STREPTOCOCCUS INFECTION;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; CYSTITIS; DRUG RESISTANCE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS; URINARY TRACT INFECTIONS;

EID: 33749080769     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13091442     Document Type: Article

References (45)

1. Hooton TM, Scholes D, Hughes JP, Winter C, Roberts PL, Stapleton AE, et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med. 1996;335:468-74.
2. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002;113 Suppl 1A:S5-13.
3. Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JD. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol. 2000;10: 509-15.
4. Foxman B, Gillespie B, Koopman J, Zhang L, Palin K, Tallman P, et al. Risk factors for second urinary tract infection among college women. Am J Epidemiol. 2000;151:1194-205.
5. Hooton TM, Besser R, Foxman B, Fritsche TR, Nicolle LE. Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy. Clin Infect Dis. 2004;39:75-80.
6. Sheinfeld J, Schaeffer AJ, Cordon-Cardo C, Rogatko A, Fair WR. Association of the Lewis blood-group phenotype with recurrent urinary tract infections in women. N Engl J Med. 1989;320:773-7.
7. Foxman B. Recurring urinary tract infection: incidence and risk factors. Am J Public Health. 1990;80:331-3.
8. Ikaheimo R, Siitonen A, Heiskanen T, Karkkainen U, Kuosmanen P, Lipponen P, et al. Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis. 1996;22:91-9.
9. Scholes D, Hooton TM, Roberts PL, Gupta K, Stapleton AE, Stamm WE. Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med. 2005;142:20-7.
10. Ki M, Park T, Choi B, Foxman B. The epidemiology of acute pyelonephritis in South Korea, 1997-1999. Am J Epidemiol. 2004;160:985-93.
11. Shortliffe LM, McCue JD. Urinary tract infection at the age extremes: pediatrics and geriatrics. Am J Med. 2002;113 Suppl 1A:S55-66.
12. Boyko EJ, Fihn SD, Scholes D, Abraham L, Monsey B. Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women. Am J Epidemiol. 2005;161:557-64.
13. Hu KK, Boyko EJ, Scholes D, Normand E, Chen CL, Grafton J, et al. Risk factors for urinary tract infections in postmenopausal women. Arch Intern Med. 2004;164:989-93.
14. Jackson SL, Boyko EJ, Scholes D, Abraham L, Gupta K, Fihn SD. Predictors of urinary tract infection after menopause: a prospective study. Am J Med. 2004;117:903-11.
15. Vorland LH, Carlson K, Aalen O. An epidemiological survey of urinary tract infections among outpatients in Northern Norway. Scand J Infect Dis. 1985;17:277-83.
16. Johnson JR, Scheutz F, Ulleryd P, Kuskowski MA, O'Bryan TT, Sandberg T. Host-pathogen relationships among Escherichia coli isolates recovered from men with febrile urinary tract infection. Clin Infect Dis. 2005;40:813-22.
17. Barnes RC, Daifuku R, Roddy RE, Stamm WE. Urinary-tract infection in sexually active homosexual men. Lancet. 1986;1:171-3.
18. Abardanel J, Engelstein D, Lask D, Livme PM. Urinary tract infection in men younger than 45 years of age: is there a need for urologic investigation? Urology. 2003;62:27-9.
19. Hooton TM, Scholes D, Gupta K, Stapleton AE, Roberts PL, Stamm WE. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. JAMA. 2005;293:949-55.
20. Raz R, Colodner R, Kunin CM. Who are you - Staphylococcus saprophyticus? Clin Infect Dis. 2005;40:896-8.
21. Andreu A, Alós JI, Gobernado M, Marco F, De la Rosa M, García-Rodríguez JA, et al. Etiología y sensibilidad a los antimicrobianos de los uropatógenos causantes de la infección urinaria baja adquirida en la comunidad. Estudio nacional multicéntrico. Enferm Infecc Microbiol Clin. 2005;23:4-9.
22. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections. The ECO-SENS Project. J Antimicrob Chemother. 2003;51:69-76.
23. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med. 2002;113 Suppl 1A:S14-9.
24. Sobel JD, Kaye D. Urinary tract infections. En: Mandell GL, Bennett JE, Dolin R, editores. Principles and practice of infectious diseases. Philadelphia: Elsevier Churchill Livingstone; 2005. p. 875-905.
25. Gupta K, Sahm DF, Mayfield D, Stamm WE. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin Infect Dis. 2001;33:89-94.
26. Goossens H, Ferech M, Vander Stichele R, Elseviers M. ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365:579-87.
27. Garau J, Xercavins M, Rodríguez-Carballeira M, Gómez-Vera JR, Coll I, Vidal D, et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother. 1999;43:2736-41.
28. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis. 1999;29:745-58.
29. Alós JI, Serrano MG, Gómez-Garcés JL, Perianes J. Antibiotic resistance of Escherichia coli from community-acquired urinary tract infections in relation to demographic and clinical data. Clin Microbiol Infect. 2005;11:199-203.
30. Alós JI, Balas D, Gómez-Garcés JL, Grupo de Estudio de Infección en Atención Primaria. Prevalencia de susceptibilidad a quinolonas y otros antibióticos en microorganismos aislados de bacteriurias extrahospitalarias de Madrid en 1995. Rev Clin Esp. 1997;197:167-71.
31. Alonso Sanz M, Abad Bécquer MI. Fenotipos de resistencia en aislamientos urinarios de Escherichia coli en la comunidad: implicaciones terapéuticas. Med Clin (Barc). 2003;120:361-4.
32. Junquera S, Loza E, Baquero F. Changes in the antimicrobial susceptibility of Escherichia coli isolates from nosocomial versus community-acquired urinary tract infections. Enferm Infecc Microbiol Clin. 2005;23:197-201.
33. Lorente Garín JA, Placer Santos J, Salvadó Costa M, Segura Álvarez C, Gelabert-Mas A. Evolución de la resistencia antibiótica en las infecciones urinarias adquiridas en la comunidad. Rev Clin Esp. 2005;205:259-64.
34. Ti TY, Kumarasinghe G, Taylor MB, Tan SL, Ee A, Chua C, et al. What is true community-acquired urinary tract infection? Comparison of pathogens identified in urine from routine outpatient specimens and from community clinics in a prospective study. Eur J Clin Microbiol Infect Dis. 2003;22:242-5.
35. Richards DA, Toop LJ, Chambers ST, Sutherland MG, Harris BH, Ikram RB, et al. Antibiotic resistance in uncomplicated urinary tract infection: problems with interpreting cumulative resistance rates from local community laboratories. N Z Med J. 2002;115:12-4.
36. Hummers-Pradier E, Koch M, Ohse AM, Heizmann WR, Kochen MM. Antibiotic resistance of urinary pathogens in female general practice patients. Scand J Infect Dis. 2005;37:256-61.
37. Ena J, Amador C, Martínez C, Ortiz de la Tabla V. Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli. J Urol. 1995;153:117-20.
38. Brown PD, Freeman A, Foxman B. Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan. Clin Infect Dis. 2002;34:1061-6.
39. Brigante G, Luzzaro F, Perilli M, Lombardi G, Coli A, Rossolini GM, et al. Evolution of CTX-M-type beta-lactamases in isolates of Escherichia coli infecting hospital and community patients. Int J Antimicrob Agents. 2005;25: 157-62.
40. Rodríguez-Baño J, Navarro MD, Romero L, Martínez- Martínez L, Muniain MA, Perea EJ, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol. 2004;42:1089-94.
41. Ferry SA, Holm SE, Stenlund H, Lundholm R, Monsen TJ. The natural course of uncomplicated lower urinary tract infection in women illustrated by a randomized placebo controlled study. Scand J Infect Dis. 2004;36: 296-301.
42. Christiaens TC, De Meyere M, Verschraegen G, Peersman W, Heytens S, De Maeseneer JM. Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br J Gen Pract. 2002;52:729-34.
43. Patel RB, Welling PG. Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole). Clin Pharmacokinet. 1980;5:405-23.
44. Raz R, Chazan B, Kennes Y, Colodner R, Rottensterich E, Dan M, et al. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis. 2002;34:1165-9.
45. Talan DA, Stamm WE, Hooton TM, Moran GJ, Burke T, Iravani A, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA. 2000;283:1583-90.